1. Riedel S, Hobden JA, Miller S, Morse SA, Mietzner TA, Mitchell TG, Sakanari JA, Hotez P, Mejia R (Eds). Antimicrobial Chemotherapy (In) Jawetz, Melnick & Adelberg’s Medical Microbio-
logy: 28th ed New York: Lange Medical Books/McGraw Hill, 2020; 379-412.
2. Walsh CT. Antibiotics, Actions, Origins, Resistance: Washington DC, ASM Press, 2003.
3. Lewis JS and Bush K. Antibacterial agents (71. Bölüm). (Section III: Antibacterial Agents and Susceptibility Test Methods (James A Karlowsky volume editor and Jean B. Patel section editor).
In Manual of Clinical Microbiology, 13 th ed., ASM Press 2023; 3376-3541
4. Macheboeuf P, Contreras-Martel C, Job V, Dideberg O, Dessen A. Penicilin Binding Proteins: key players in bacterial cell cycle and drug resistance processes. FEMS Microbiol Rev 2006;
30:673-91.
5. Rice LB, Bonomo RA. Mechanism of resistance to antibacterial agents. In: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA. (eds). Manual of Clinical Microbiology. Washington
DC: ASM Press, 2007:1114-45.
6. Bayles KW. The bactericidal action of penicillin: new clues to an unsolved mystery. Trends Microbiol 2000; 8:274-8.
7. Sanford Guide Web edition https://web.sanfordguide.com/en/drug-information/antibacterial-agents/penicillins (Giriş tarihi 2025)
8. Chambers HF. Penicillins. In: Mandell GL, Bennett JE, Dolin R (eds). Principles and Practice of Infectious Diseases. Philadelphia: Churchill and Livingstone, 2000:261.
9. Poon H, Chang MH, Fung HB. Ceftaroline fosamil; a cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Ther 2012; 34:743-65.
10. Walkty A, Adam HJ, Laverdiere M et al. In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative pathogens. Diagn Microbiol
Infect Dis 2011; 69:348-55.
11. Wicky, P.-H.; Poiraud, J.; Alves, M.; Patrier, J.; d’Humières, C.; Lê, M.; Kramer, L.; de Montmollin, É.; Massias, L.; Armand-Lefèvre, L.; et al. Cefiderocol Treatment for Severe Infections due to
Difficult-to-Treat-Resistant Non-Fermentative Gram-Negative Bacilli in ICU Patients: A Case Series and Narrative Literature Review. Antibiotics 2023, 12, 991.
12. Queenan AM, Shang W, Flamm R, Bush K. Hydrolysis and inhibition profiles of beta-lactamase from molecular classes A to D with doripenem, imipenem and meropenem. Antimicrob
Agents Chemother 2010; 54:565-9.
13. Papp-Wallace KM, Endimiani A, Taraclia MA, Bonomo RA. Carbapenems: past, present and future. Antimicrob Agents Chemother 2011; 55:4943-60.
14. Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998; 11:57-80.
15. Alfei S, Schito AM. β-Lactam Antibiotics and β-Lactamase Enzymes Inhibitors, Part 2: Our Limited Resources. Pharmaceuticals (Basel). 2022; 15(4):476. doi: 10.3390/ph15040476.
16. Zhang S, Liao X, Ding T, Ahn J. Role of β-Lactamase Inhibitors as Potentiators in Antimicrobial Chemotherapy Targeting Gram-Negative Bacteria. Antibiotics. 2024; 13(3):260. https://doi.
org/10.3390/antibiotics13030260
17. Luci G, Mattioli F, Falcone M, Di Paolo A. Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors. Antibiotics (Basel). 2021;10(7):769. doi: 10.3390/antibiotics10070769.
18. Mojica MF, Rossi MA, Vila AJ, Bonomo RA. The urgent need for metallo-β-lactamase inhibitors: an unattended global threat. Lancet Infect Dis. 2022;22(1): e28-e34. doi: 10.1016/S1473-
3099(20)30868-9.
19. https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-pfizers-emblaveor-patients (Son Erişim Tarihi: 03 Eylül 2024).
20. https://www.titck.gov.tr/dinamikmodul/85 (Son Erişim Tarihi: 09 Eylül 2024).
21. Arman D. Glikopeptit ve lipopeptit antibiyotikler. ANKEM Derg 2006;20(Ek 2):112-6.
22. Zhanel GG, Schweizer Karlowski FA: Oritavancin: mechanism of action. Clin Infect Dis 2012, 54(Suppl 3): S214-9.
23. Warren ER, Fallon M, Moran JJM, Vanderlooa JP. Vancomycin tolerance in methicillin-resistant Staphylococcus aureus: influence of vancomycin, daptomycin, and telavancin on differential
resistance gene expression. Antimicrob Agents Chemother 2012; 56:4422-7.
24. Pullukçu H, Taşbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extended spectrum beta-lactamase producing Escherichia coli-related lower urinary
tract infections. Int J Antimicrob Agents 2007; 29:62-5.
25. https://www.eucast.org/clinical_breakpoints
26. Roberts MC, Sutcliffe J. Macrolide, lincosamide, streptogramin, ketolide, and oxazolidinone resistance. In: White DG, Alekshun MN, McDermott PF (eds). Frontiers in Antimicrobial Resis-
tance. Washington DC, ASM Press, 2005:66-84.
27. Wimberly BT, Brodersen DE, Clemons WM et al. Structure of 30S ribosomal subunit. Nature 2000; 407:327-39.
28. Nissen P, Hansen J, Ban N, Moore PB, Seitz TA. The structural basis of ribosome activity in peptide bond synthesis. Science 2000; 289:920-30.
29. Yusupova GZ, Yusupov MM, Cate HJD, Noller HF. The path of messenger RNA through the ribosome. Cell 2001; 106:233-41.
30. Rodnina MW, Wintermayer W. Ribosome fidelity; tRNA discrimination, proof reading and induced fit. Trends Biochem Sci 2001; 26:124-30.
31. Lonks JR, Goldmann DA. Telithromycin; a ketolide antibiotic for treatment of respiratory tract infections. Clin Infect Dis 2005; 40:1657-64.
32. Livermore DM. Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? J Antimicrob Chemother 2000; 46:347-50.
33. Patel U, Yan YP, Hobbs FW. Oxazolidinones mechanism of action: inhibition of the first peptide bond formation. J Biol Chem 2001; 276:37199-205.
34. Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.
JAMA 2013; 309:559-69.
35. Bassetti M, Merellli M, Temperoni C, Astilean A. New antibiotics for bad bugs; where are we? Ann Clin Microbiol Antimicrob 2013; 12:22.
36 . Carter AP, Clemons WM, Brodersen DE. Functional insights from the structure of the ribosomal subunit and its interactions with antibiotics. Nature 2000; 407:340-8.
37 Clark JA., Burgess DS Plazomicin: a new aminoglycoside in the fight against antimicrobial resistance. Ther Adv Infectious Dis 2020; 7: 1–15
38. Panley GA. Tigecycline. J Antimicrob Chemother 2005; 56:470-8.
39. Bouchillon SK, Hoban DJ, Johnson BM et al. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and
Surveillance Trial (TEST Program; 2004). Diagn Microbiol Infect Dis 2005; 52:173-9.
40. Alekshun MN. Tetracyclines and resistance. In: White DG, Alekshun MN, McDermott PF (eds). Frontiers in Antimicrobial Resistance. Washington DC, ASM Press, 2005:3-18.
41. Cunha BA. New uses for older antibiotics: nitrofurantoin, amikacin, colistin, polymyxin B, doxycycline, and minocycline. Med Clin North Am 2006; 90:1089-107.
42. Sader HS, Bechenbach DJ, Paulner S, Jones RN. Antimicrobial activity of the investigational pleuromutilin compound BC3781 tested against gram-positive organisms commonly associated
with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 2012;563:1619-23.
43. Hooper DC. New uses for new and old quinolones and the challenge of resistance. Clin Infect Dis 2000; 30:243-54.
44. Shi, Z.; Zhang, J.; Tian, L.; Xin, L.; Liang, C.; Ren, X.; Li, M. A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects. Molecules 2023, 28,
1762.
45. Campbell EA, Korzheva N, Mustaev A. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 2001; 104:901-12.
46. Samuelson J. Why metronidazole is active against both bacteria and parasites. Antimicrob Agents Chemother 1999; 43:1533-41.
47. Woods GL, Warren NG, Inderlied CB. Susceptibility test methods: Mycobacteria, Nocardia and other Actinomycetes. In: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA. (eds).
Manual of Clinical Microbiology. Washington DC: ASM Press, 2007:1223-47.
48. Velkov T, Thompson PE, Nation RL, Li J. Structure-activity relationships of polymyxin antibiotics. J Med Chem 2010; 53:1898-916.
49. Gurjar M. Colistin for lung infection: an update. J Intensive Care 2015; 3:3.
50. Batirel A, Balkan II, Karabay O, et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acine-
tobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis 2014; 33:1311-22.
51. McAuliffe O, Ross RP, Hill C. Lantibiotics:structure, biosynthesis and mode of action FEMS Microbiology Reviews, 2001; 25; 285–30
52. Puls JS, Winnerling B, Power JJ, Krüger AM, Brajtenbach D et al. Staphylococcus epidermidis bacteriocin A37 kills natural competitors with a unique mechanism of action. The ISME Journal,
2024; 188 (1).
53. French GL. Bactericidal agents in the treatment of MRSA infections – the potential role of daptomycin. J Antimicrob Chemother 2006; 58:1107-17.